- 1 Full title: Acute kidney injury outcomes of COVID-19 confirmed patients in a
- 2 Philippine tertiary hospital: A retrospective study
- 3 Short title: Acute kidney injury outcomes in COVID-19
- 4 Author list: Joberly Sayson,^{1*¶} Reginald Kalaw,^{1¶} Bernadette Ecunar Ordona,^{1¶}
- 5 Marissa Elizabeth Lim¹¶
- 6
- ⁷ ¹Section of Nephrology, Department of Internal Medicine, East Avenue Medical
- 8 Center, Quezon City, Metro Manila,
- 9 [¶] These authors contributed equally to this work.
- 10
- 11 Corresponding author
- 12 Joberly Sayson
- 13 Email: joberly_sayson@yahoo.com
- 14
- 15
- 16
- 17
- 18
- 19
- -
- 20
- 21
- 22
- 23
- 24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 Abstract

28	The novel coronavirus (COVID-19) is known to be the fifth pandemic causing
29	massive deaths worldwide. This virus has not only been deeply associated with acute
30	respiratory distress, but also acute kidney injury (AKI). This study describes the
31	baseline characteristics and various outcomes of AKI based on the KDIGO 2012
32	Clinical Practice Guidelines in patients hospitalized with COVID-19 at a Philippine
33	tertiary hospital. A total of 195 patient records were retrospectively reviewed for the
34	study. Of the 195 patients, 81(42%) patients developed AKI. Significant baseline
35	characteristics included older age (56.28 + 14.12), presence of hypertension
36	(p=0.004), diabetes mellitus (p=0.002), and cardiovascular disease (p=0.003). Also,
37	the use of diuretics, inotropes and antibiotics were more prevalent in patients who
38	developed AKI. Most of the patients who had AKI were categorized as stage 1
39	(49.38%). Mechanical ventilation was significantly (p<0.001) more prevalent in
40	patients with AKI (20.99%) compared to patients without AKI (5.26%). There was
41	significantly higher rates (p<0.001) of renal replacement therapy in patients with AKI
42	(30.86%). Lastly, higher mortality rates were observed in patients with AKI (50.62%)
43	versus patients without AKI (12.28%). Our study demonstrated that patients with
44	COVID-19 can develop AKI and tend to have a poorer prognosis.
45	

- 46

47 Introduction

48	At the end of 2019, cases of a novel human pneumonia were first reported in
49	Wuhan, China where patients reported symptoms of malaise, dry cough, dyspnea, and
50	fever, with some requiring intensive care for severe and acute respiratory distress. The
51	coronavirus disease of 2019 (COVID-19) quickly spread worldwide becoming the
52	fifth recognized pandemic following the 1918 flu contagion [1]. The World Health
53	Organization (WHO) reports that the number of COVID-19 cases has peaked at 767
54	million, with approximately 7 million deaths around the world since the start of the
55	pandemic [2]. In the Philippines, the cumulative cases rose to more than 4 million
56	with over 66,000 total deaths [2].
57	The coronaviruses are large, enveloped, single-stranded RNA viruses usually
58	found in mammals such as dogs, cats, and humans. They cause neurologic,
59	respiratory, and gastrointestinal diseases [3]. The Severe Acute Respiratory
60	Syndrome Coronavirus-2 (SARS-CoV-2), in particular, is known to target the
61	epithelial cells and pneumocytes of the nasal and bronchial areas through the viral
62	structural spike (S) protein that binds to angiotensin-converting enzyme 2 (ACE 2)
63	receptor [4]. Viral uptake is facilitated by cleaving the ACE 2 and activating the S
64	protein of the virus [4]. Once within the cell, it promotes a cascade of events that
65	trigger the inflammatory response, resulting in the disruption of the epithelial-
66	endothelial integrity of the lungs. This eventually leads to acute respiratory distress
67	syndrome (ARDS) [5].
68	In the kidneys, the virus can directly damage the renal tubular epithelium and
69	podocytes through the ACE 2-dependent pathway. Viral invasion results in
70	mitochondrial dysfunction, collapsing glomerulopathy, acute tubular necrosis, and
71	protein leakage in the Bowman's Capsule leading to acute kidney injury (AKI) [6].

72	These processes along with other factors, such as sepsis, hypovolemia, and
73	cardiorenal syndrome, amplify the insult to the kidneys [7]. COVID-19 is also known
74	to activate cytokine release syndrome (CRS), a phenomenon associated with the
75	release of pro-inflammatory cytokines, such as interleukin-6, which could lead to
76	systemic endothelial injury further impacting the kidneys [8]. Another mechanism
77	that is known to be contributory is the organ crosstalk occurring between the
78	cardiopulmonary system and the kidneys [9]. Hypoxemia resulting from ARDS and
79	hypoperfusion due to COVID-19-related cardiac pathology may result in further
80	damage to the renal tubules [10].
81	A meta-analysis of 44 studies conducted by Sabaghian et al reported AKI
82	incidence to be as high as 56.2% in hospitalized COVID-19 patients and 75.5% after
83	admission. The median age was reported to be 63 years, and over 40% had an existing
84	comorbidity, such as CKD, chronic obstructive pulmonary disease, hypertension,
85	diabetes, and tumors [11]. Proteinuria of any degree, hematuria of any degree,
86	elevated baseline blood urea nitrogen (BUN), serum creatinine, peak serum creatinine
87	$>133~\mu mol/l,$ and AKI over stage 2 were associated with in-hospital death after
88	adjusting for age, sex, disease severity, comorbidities, and lymphocyte count [11].
89	Various studies have established the intrinsic association of AKI with poor prognosis
90	(i.e., up to 83% at 5 years) and higher risk for mortality immaterial of pre-AKI
91	baseline (hazard ratio [HR] 1.08 to 4.59) or recovery of renal function (HR 1.08 to
92	5.75) [12]. However, in patients with COVID-19 and AKI, there appears to be a 13-
93	fold increased risk of mortality [13] with an estimated overall hospital mortality rate
94	of 66.2% [11]. Among the several reasons for higher mortality were severe sepsis-
95	related multi-organ failure, direct kidney involvement, and acute respiratory distress
96	syndrome [14].

97	AKI in some COVID-19-confirmed patients may prompt the need for renal
98	replacement therapy (RRT) or even a kidney transplant. The impact of these outcomes
99	is more apparent in resource-limited settings, such as in the Philippine healthcare
100	system [15]. AKI in COVID-19 encumbers the healthcare system by directly affecting
101	the efficient utilization of hemodialysis machines, staff, and other hospital resources.
102	Also, long-term monitoring is needed to avoid the progression of AKI to chronic
103	kidney disease (CKD) and reduce the associated mortality in high-risk populations
104	[15]. As such, it is important to recognize means to promptly identify and prevent
105	further renal injury and facilitate recovery of renal function in patients with and who
106	are recovering from COVID-19 [16].
107	In this study, we aimed to determine the clinical outcomes of patients who
108	developed AKI in a tertiary hospital setting in the Philippines based on the Kidney
109	Disease Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines
110	AKI classification system. We sought to identify the baseline demographic profile of
111	COVID-19 patients and determine the outcome in those who develop AKI and at
112	what stage could lead to poorer outcomes. With this, we hope that our clinicians be
113	guided in their clinical approach and prognostication of patients with greater risk for
114	AKI to reduce or shorten the need for RRT and avoid complications like prolonged
115	hospitalizations, development of CKD, as well as death.
116	Materials and methods
117	Study design

118 This is a retrospective cohort study that included a review of charts of all

119 confirmed COVID-19 patients based on the result of their reverse transcription

120 polymerase chain reaction (RT-PCR) test from 1 March 2020 to 31 December 2020.

121 Baseline data, including age, co-morbidities, admission serum BUN and creatinine,

122 urinalysis, and urine output monitoring were obtained. Data on medications during the

123 hospital stay of the patients were also gathered. Outcomes such as discharge, death,

- 124 and the need for assisted ventilation (e.g., high-flow nasal cannula, or mechanical
- 125 ventilation) were collected (Fig. 1).
- 126 Patients who decided to go home against medical advice, had no baseline
- 127 (within 24 hours upon admission) serum BUN and creatinine measurements, had
- 128 undergone maintenance hemodialysis before admission, and had a history of urinary
- 129 tract obstruction before admission were excluded.
- 130 Sampling and sample size
- A minimum of 185 patients were required for this study based on a 3.1%
- prevalence of AKI among patients with COVID-19 disease [17], and a 5% level of

133 significance, and a 2.5% desired width of a confidence interval were set. A purposive

134 sampling technique was employed with a total of 195 patients enrolled.

135 Data gathering and ethical considerations

136 The study was submitted to the East Avenue Medical Center (EAMC)

137 Institutional Ethics Review Board (IERB) for approval prior to the actual data

138 collection and was conducted in compliance with the Philippine Data Privacy Act of

139 2012. A waiver of informed consent was requested and granted by the IERB. Only the

- 140 primary investigator was involved in the collection of data. Patients included in the
- study were anonymized in the data collection form and only the case number and code

142 numbers were used. General data, clinical features and laboratory results were

- 143 extracted from the charts and recorded. The data gathered were then stored in a
- 144 password-protected computer and stored in a lock and key cabinet. Data will be
- 145 disposed via the secure delete feature as included in the operating system of the

146 computer and documents used will be subjected to paper shredding 3 years after study147 initiation.

148 The list of COVID-19-confirmed patients from March 2020 to December 149 2020 was obtained from the Public Health Unit of a Philippine tertiary hospital, the 150 EAMC in Quezon City. After, the charts of these patients were retrieved from the 151 Medical Records for data collection. Baseline demographics such as age, gender, and 152 co-morbidities such as hypertension, diabetes mellitus, and cardiac diseases, were 153 documented. Serum BUN and creatinine levels determined within 24 hours of 154 admission, as well as AKI findings during their hospital stay, were obtained, and 155 classified based on the criteria of the KDIGO guidelines. Urinalysis and urine output 156 monitoring were part of the data collection form. Medications given to the patients 157 while admitted were likewise noted. 158 Patients were classified according to whether they developed AKI, whether

they were discharged, expired, whether they required a high-flow nasal cannula or amechanical ventilator, and their length of stay at the hospital recorded.

161 Data processing and statistical analysis

162 Descriptive statistics were used to summarize the demographic and clinical 163 characteristics of the patients. Frequency and proportion were used for categorical 164 variables, median and interguartile range for non-normally distributed continuous 165 variables and mean and SD for normally distributed continuous variables. An 166 independent sample T-test, Mann-Whitney U test, and Fisher's Exact/Chi-square test 167 were used to determine the difference in mean, rank, and frequency, respectively, 168 between the control and experimental groups. All statistical tests were two-tailed 169 tests. The Shapiro-Wilk test was used to evaluate the normality of the continuous 170 variables. Missing values were neither replaced nor estimated. The null hypotheses

171 were rejected at a 0.05 level of significance. Lastly, the Stata 13.1 program was used

- 172 for data analysis.
- 173 **Results**

174	Patients with AKI were significantly older (56.28 ± 14.12 ; P<0.001) compared
175	with patients without AKI (47.91 \pm 14.72). There was no significant difference in the
176	rates of AKI between male and female genders. Additionally, comorbidities, such as
177	hypertension (p=0.004), diabetes mellitus (p=0.002), and cardiovascular disease
178	(p=0.003), were significantly more prevalent in patients with AKI compared to
179	patients without AKI, at 58.02% vs. 36.84%, 32.1 vs. 13.16%, 20.99 vs. 6.14%,
180	respectively. Baseline creatinine clearance based on the Chronic Kidney Disease
181	Epidemiology Collaboration (CKD-EPI) criteria showed that an estimated glomerular
182	filtration rate (eGFR) of >90 (p<0.001) was significantly associated with AKI.
183	Diuretics (p=0.001), inotropes (p=0.001), and the use of antibiotics were more
184	prevalent in patients who developed AKI vs. non-AKI patients (34.57% vs. 13.16%,
185	20.99% vs. 5.26% and 100% vs. 85.09%, respectively).
186	
187	Table 2 shows urinalysis results in patients with AKI vs. non-AKI, namely, the
188	macroscopic and microscopic findings, chemical tests, and presence of crystals.
189	Microscopic analysis reveals that AKI patients had significantly higher rates of hazy
190	to turbid urine (p=0.042) vs. non-AKI patients. The presence of blood was likewise
191	significantly higher (p=0.047) in those with AKI vs. non-AKI. The existence of
192	bacteria (p=0.038) and amorphous urates (p=0.001) between AKI and non-AKI
193	patients were also significantly different.

194

Table 3 outlines that out of the 195 subjects reviewed, 81 developed AKI, the majority of whom developed stage 1 AKI. Table 4 shows the different outcomes in

197 patients who developed AKI vs. those who did not develop AKI. There was 198 significantly (p<0.001) greater mortality in patients with AKI (50.62%) vs. patients 199 without AKI (12.28%). The length of hospital stay was not significant between AKI 200 and non-AKI patients with an average hospital stay of 21 days. There was no 201 significant difference among patients hooked to nasal cannula, facemask, or high-flow 202 nasal cannula between AKI and non-AKI individuals. Mechanical ventilation was 203 significantly (p < 0.001) more prevalent in patients with AKI (20.99%) compared to 204 patients without AKI (5.26%). There were significantly (p < 0.001) more RRT cases in 205 patients with AKI (30.86%) vs. patients without AKI (1.75%). The two patients who 206 had undergone RRT without the development of AKI were those who had undergone 207 isolated ultrafiltration while on hemoperfusion.

Table 5 demonstrates that there were more mortalities in stage 3 AKI while more discharges were observed in stage 1 AKI. The length of hospital stay was similar for the three stages. Most patients who had undergone RRT are in AKI stage 3, the seven patients who underwent RRT for stage 1 and stage 2 were patients who had undergone hemoperfusion, overlapping with hemodialysis.

213

214 Discussion

Our study has outlined the number of patients who developed AKI, their baseline characteristics, outcomes, and those who underwent RRT in patients admitted for COVID-19 at the EAMC from March to December 2020. The EAMC is one of the largest hospitals to admit COVID-19 patients in Metro Manila. Of the 195 patients included in the study, 81 (41.5%) of them developed AKI. These findings mirror the results of a US study where 49.3% of patients who had COVID-19 developed AKI [18]. Out of the 81 patients in our study who developed AKI, a

majority (49.38%) developed stage 1, followed by the development of stage 3 which
is 35.8%, and lastly by stage 2 which is 14.81%.

224 Several studies have confirmed that age is a factor for the development of AKI 225 in COVID-19. For instance, in the study of Nimkar and colleagues, it was shown that 226 the median age of the patients was 71 years [19] while it was 61 years old for the 227 study of Fominsky et al [20]. Most individuals admitted for COVID-19 at our center 228 tended to be older (56.28 ± 14.12) . The significant comorbidities include 229 hypertension, diabetes mellitus and cardiovascular diseases (58.02%, 32.1% and 230 20.99% respectively). This is consistent with the study conducted by Sargiacomo et al 231 associating worse outcomes with these comorbid illnesses and they represent risk 232 factors for the development of AKI [21].

233 Several factors may predispose the critically ill to the development of AKI in 234 COVID-19. Hypoperfusion of the kidneys secondary to shock resulting from sepsis, hypovolemia, or cardiogenic etiologies, especially in patients with underlying cardiac 235 236 disease, may be one of the causes [22]. On the other hand, pre-existing COPD was not 237 seen as a predisposing factor in our study. As for medications used at the time of 238 admission, diuretics, inotropes, and antibiotics tended to be more significantly 239 prevalent in patients who developed AKI compared with other medications such as 240 steroids, ACEi/ARBs, antivirals and NSAIDs. In a study by Nadim et al, the 241 medications that were found to be contributory to AKI development include 242 antibiotics, contrast media, and NSAIDs. They attributed the development of AKI 243 acute tubular injury [23].

244 Cheng et al observed that hematuria and proteinuria were associated with a 245 threefold and almost twofold increase in the risk of AKI in COVID-19 patients; 246 however, this was not replicated in our study [24]. We do note that urine transparency

and the microscopic presence of red blood cells (RBCs) are associated with AKI. In a
Turkish study, histopathological findings in kidneys of COVID-19 patients include
the presence of viral particles in the proximal tubules, podocytes with varying degrees
of acute tubular necrosis and loss of brush borders, vacuolar degeneration and the
accumulation of RBCs [25], possibly supporting these findings.

Patients who developed AKI tended to have poorer prognosis with most of them succumbing to death (50.62% vs. 12.28%). This is more apparent in those who developed AKI stage 3 (72.41% vs. 27.59%). Like the systematic review by Ali et al, mortality was significantly higher in patients with AKI [26]. The length of hospital stay appears to have no bearing on the development of AKI in COVID-19.

Organ crosstalk appears to be the mechanism implicated in the involvement between alveolar and tubular damage as they are both contributory to interleukin-6 (IL-6) overproduction [9]. This may be the underlying reason for the association between mechanical ventilation and AKI. Aside from organ crosstalk, pulmonary inflammation may lead to the release of pro-apoptotic and pro-inflammatory substances that may lead to AKI [22].

Most importantly, out of our 81 patients who developed AKI, 25 underwent RRT (30.9%) where 18 had stage 3 AKI while seven underwent RRT while undergoing hemoperfusion. Because of this, we reiterate the importance of close monitoring in patients with AKI to prevent the need for RRT.

We acknowledge that our study has some limitations. Firstly, our analysis was limited to a retrospective cohort and as such, comes with the limitations inevitably linked with this type of study. Secondly, laboratory findings, such as urinalysis results were not uniformly available in all patients, while serum creatinine and blood urea

nitrogen (BUN) levels were not regularly monitored. Lastly, no post discharge follow-up was conducted in our study.

273

274 Conclusions

Our study demonstrated that patients with COVID-19 can develop AKI and tend to have a poorer prognosis, including death, especially at stage 3 AKI. Older age, the presence of hypertension, diabetes mellitus, and cardiovascular disease can be risk factors for the development of AKI as well as the use of diuretics, inotropes, and antibiotics. The development of AKI in COVID-19 patients can lead to RRT and monitoring renal function after recovery from AKI is important to avoid progression to chronic renal failure.

282

283 Acknowledgments

- We thank our mentors and colleagues at the Section of Nephrology of the
- EAMC for their support and guidance.

286

287 References

- 288 1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus
- 289 pandemic in history. Biomed J. 2020;43: 328-333. Epub 20200505. doi:
- 290 10.1016/j.bj.2020.04.007
- 291 2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard
- 292 [Internet]. Available from: <u>https://covid19.who.int/</u>.
- 293 3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.
- 294 Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019
- 295 (COVID-19): A review. JAMA. 2020;324: 782-793. doi: 10.1001/jama.2020.12839

- 296 4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S,
- et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a
- clinically proven protease inhibitor. Cell. 2020;181: 271-280 e278. Epub 20200305.
- 299 doi: 10.1016/j.cell.2020.02.052
- 300 5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings
- 301 of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir
- 302 Med. 2020;8: 420-422. Epub 20200218. doi: 10.1016/S2213-2600(20)30076-X
- 303 6. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological
- analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int.
- 305 2020;98: 219-227. Epub 20200409. doi: 10.1016/j.kint.2020.04.003
- 306 7. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394:
- 307 1949-1964. doi: 10.1016/S0140-6736(19)32563-2
- 308 8. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for
- 309 extracorporeal therapies. Nat Rev Nephrol. 2020;16: 308-310. doi: 10.1038/s41581-
- 310 020-0284-7
- 311 9. Panitchote A, Mehkri O, Hastings A, Hanane T, Demirjian S, Torbic H, et al.
- 312 Factors associated with acute kidney injury in acute respiratory distress syndrome.
- 313 Ann Intensive Care. 2019;9: 74. Epub 20190701. doi: 10.1186/s13613-019-0552-5
- 314 10. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja
- 315 MM, Ardalan M, et al. COVID-19 and kidney injury: Pathophysiology and molecular
- 316 mechanisms. Rev Med Virol. 2021;31: e2176. Epub 20201006. doi:
- 317 10.1002/rmv.2176
- 318 11. Sabaghian T, Kharazmi AB, Ansari A, Omidi F, Kazemi SN, Hajikhani B, et
- al. COVID-19 and acute kidney injury: A systematic review. Front Med (Lausanne).
- 320 2022;9: 705908. Epub 20220404. doi: 10.3389/fmed.2022.705908

321 12. Sawhney S, Mitchell M, Marks A, Fluck N, Black C. Long-term prognosis 322 after acute kidney injury (AKI): what is the role of baseline kidney function and 323 recovery? A systematic review. BMJ Open. 2015;5: e006497. Epub 20150106. doi: 324 10.1136/bmjopen-2014-006497 325 Hansrivijit P, Qian C, Boonpheng B, Thongprayoon C, Vallabhajosyula S, 13. 326 Cheungpasitporn W, et al. Incidence of acute kidney injury and its association with 327 mortality in patients with COVID-19: a meta-analysis. J Investig Med. 2020;68: 328 1261-1270. Epub 20200712. doi: 10.1136/jim-2020-001407 329 14. Chen YT, Shao SC, Lai EC, Hung MJ, Chen YC. Mortality rate of acute 330 kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and 331 meta-analysis. Crit Care. 2020;24: 439. Epub 20200716. doi: 10.1186/s13054-020-332 03134-8 333 Tannor EK, Bajpai D, Nlandu YM, Wijewickrama E. COVID-19 and kidney 15. disease: Progress in health inequity from low-income settings. Semin Nephrol. 334 335 2022;42: 151318. Epub 20230116. doi: 10.1016/j.semnephrol.2023.151318 336 Rudd KE, Cizmeci EA, Galli GM, Lundeg G, Schultz MJ, Papali A. Pragmatic 16. 337 recommendations for the prevention and treatment of acute kidney injury in patients 338 with COVID-19 in low- and middle-income countries. Am J Trop Med Hyg. 339 2021;104: 87-98. Epub 20210111. doi: 10.4269/ajtmh.20-1242 340 17. Kutluhan MA, Tas A, Sahin A, Urkmez A, Topaktas R, Atac O, et al. 341 Assessment of clinical features and renal functions in Coronavirus disease-19: A 342 retrospective analysis of 96 patients. Int J Clin Pract. 2020;74: e13636. Epub 343 20200907. doi: 10.1111/ijcp.13636 344 Pelayo J, Lo KB, Bhargav R, Gul F, Peterson E, DeJoy Iii R, et al. Clinical 18. characteristics and outcomes of community- and hospital-acquired acute kidney injury 345

with COVID-19 in a US inner city hospital system. Cardiorenal Med. 2020;10: 223-

- 347 231. Epub 20200618. doi: 10.1159/000509182
- 348 19. Nimkar A, Naaraayan A, Hasan A, Pant S, Durdevic M, Suarez CN, et al.
- 349 Incidence and risk factors for acute kidney injury and its effect on mortality in
- atients hospitalized from COVID-19. Mayo Clin Proc Innov Qual Outcomes.
- 351 2020;4: 687-695. Epub 20200719. doi: 10.1016/j.mayocpiqo.2020.07.003
- 352 20. Fominskiy EV, Scandroglio AM, Monti G, Calabro MG, Landoni G,
- 353 Dell'Acqua A, et al. Prevalence, characteristics, risk factors, and outcomes of
- invasively ventilated COVID-19 patients with acute kidney injury and renal
- 355 replacement therapy. Blood Purif. 2021;50: 102-109. Epub 20200713. doi:
- 356 10.1159/000508657
- 357 21. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging:
- 358 senolytics and other anti-aging drugs for the treatment or prevention of corona virus
- 359 infection? Aging (Albany NY). 2020;12: 6511-6517. Epub 20200330. doi:
- 360 10.18632/aging.103001
- 361 22. See YP, Young BE, Ang LW, Ooi XY, Chan CP, Looi WL, et al. Risk factors
- 362 for development of acute kidney injury in COVID-19 patients: A retrospective
- 363 observational cohort study. Nephron. 2021;145: 256-264. Epub 20210329. doi:
- 364 10.1159/000514064
- 365 23. Nadim MK, Forni LG, Mehta RL, Connor MJ, Jr., Liu KD, Ostermann M, et
- al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute
- 367 Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16: 747-764.
- 368 Epub 20201015. doi: 10.1038/s41581-020-00356-5

- 369 24. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease
- is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:
- 371 829-838. Epub 20200320. doi: 10.1016/j.kint.2020.03.005
- 25. Ertuğlu LA, Kanbay A, Afşar B, Elsürer Afşar R, Kanbay M. COVID-19 and
- acute kidney injury. Tuberk Toraks. 2020;68: 407-418. doi: 10.5578/tt.70010
- 26. Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al.
- 375 Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic
- 376 review and meta-analysis. Ren Fail. 2020;42: 393-397. doi:
- 377 10.1080/0886022x.2020.1756323
- 378
- 379
- 380
- 381

382 Figure legends

383 Figure 1. Subject selection process

- 384 This figure outlines a summary of our study's inclusion and exclusion process and
- demonstrates the clinical outcomes of COVID-19 patients admitted at the EAMC.

387 Tables

Table 1. Baseline Characteristics of COVID-19 Confirmed Patients 388

	Total	With AKI	Without AKI	
	(n=195)	(n=81, 42%)	(n=114, 58%)	p-value
	Frequ	iency (%); Mear	n ± SD	
Age	51.39 ± 15.02	56.28 ± 14.12	47.91 ± 14.72	<0.001
Gender				0.147
Male	103 (52.82)	48 (59.26)	55 (48.25)	
Female	92 (47.18)	33 (40.74)	59 (51.75)	
Comorbidities				
Hypertension	89 (45.64)	47 (58.02)	42 (36.84)	0.004
Diabetes Mellitus	41 (21.03)	26 (32.1)	15 (13.16)	0.002
Cardiovascular	24 (12.31)	17 (20.99)	7 (6.14)	0.003
Disease	20 (10.26)	9 (9.88)	12 (10.53)	1.000
COPD	11 (5.64)	5 (6.17)	6 (5.26)	0.765
eGFR by CKD-EPI	85.6 (58 to	50.6 (26 to	98.4 (84 to	< 0.001
·	103)	70)	112)	
>90	25 (12.82)	24 (29.63)	1 (0.88)	<0.001
60 to 89	10 (5.13)	10 (12.35)	0	
45 to 59	17 (8.72)	13 (16.05)	4 (3.51)	
30 to 44	53 (27.18)	18 (22.22)	35 (30.70)	
< 30 to >15	90 (46.15)	16 (19.75)	74 (64.91)	
Medication	· · ·			
Diuretic	43 (22.05)	28 (34.57)	15 (13.16)	0.001
Inotropes	23 (11.79)	17 (20.99)	6 (5.26)	0.001
Antibiotics	2 (1 to 2)	2 (1 to 2)	1 (1 to 2)	0.094
With	178 (91.28)	81 (100)	97 (85.09)	<0.001
Without	17 (8.72)	0	17 (14.91)	
Antiviral	20 (10.26)	9 (11.11)	11 (9.65)	0.813
NSAIDs	13 (6.67)	4 (4.94)	9 (7.89)	0.563
Sedation	1 (0.51)	1 (1.23)	0	0.41
Steroids	80 (41.03)	40 (49.38)	40 (35.09)	0.055
ACEi/ARB	69 (35.48)	33 (40.74)	36 (31.58)	0.224

389

ACEi, angiotensin-converting enzyme inhibitors; AKI, acute kidney injury; ARB, 390

391 angiotensin II receptor blockers; eGFR by CKD-EPI, estimated glomerular filtration

392 rate by the Chronic Kidney Disease Epidemiology Collaboration; SD, standard

393 deviation

	Total (n=195)	With AKI (n=81, 42%)	Without (n=114, s	
	I	Frequency (%); Me	edian (IQR)	
Macroscopic				
Color				0.6
Yellow	58 (67.44)	34 (69.39)	24 (64.86)	
Light Yellow	13 (15.12)	8 (16.33)	5 (13.51)	
Dark Yellow	11 (12.79)	6 (12.24)	5 (13.51)	
Amber	4 (4.65)	1 (2.04)	3 (8.11)	
Transparency				0.0
Hazy	59 (68.6)	35 (71.43)	24 (64.86)	
Turbid	15 (17.44)	11 (22.45)	4 (10.81)	
Clear	12 (13.95)	3 (6.12)	9 (24.32)	
рН	6 (5 to 6)	6 (5 to 6)	6 (6 to 7)	0.0
Specific Gravity	1.03 (1.02 to 1.03)	1.03 (1.02 to 1.03)	1.02 (1.02 to 1.03)	0.2
Chemical tests		, , , , , , , , , , , , , , , , , , ,		
Glucose (n=86)				0.1
Negative and Trace	68 (79.07)	36 (73.47)	32 (86.49)	
1	8 (9.3)	7 (14.29)	1 (2.7)	
2	8 (9.3)	5 (10.2)	3 (8.11)	
3	1 (1.16)	1 (2.04)	0	
4	1 (1.16)	0	1 (2.7)	
$\mathbf{D}_{\mathbf{r}}(\mathbf{r}=0)$				0.1
Protein (n=86)	50 (50 1 4)	25(51.02)	25((7.57))	0.1
Negative and Trace	50 (58.14)	25 (51.02)	25 (67.57)	
1	23 (26.74)	17 (34.69)	6 (16.22)	
2 3	12 (13.95) 1 (1.16)	6 (12.24) 1 (2.04)	6 (16.22) 0	

Blood (n=81)				0.047
Negative and Trace	68 (83.95)	34 (75.56)	34 (94.44)	
1	2 (2.47)	2 (4.44)	0	
2	4 (4.94)	2 (4.44)	2 (5.56)	
3 4	6 (7.41)	6 (13.33)	0	
4	1 (1.23)	1 (2.22)	0	
Ketones (n=82)				0.434
Negative and Trace	74 (90.24)	41 (91.11)	33 (89.19)	
1	5 (6.1)	2 (4.44)	3 (8.11)	
2	2 (2.44)	2 (4.44)	0	
3	1 (1.22)	0	1 (2.7)	
Nitrate (n=82)				1.000
Negative and Trace	81 (98.78)	44 (97.78)	37 (100)	
1	1 (1.22)	1 (2.22)	0	
Bilirubin (n=82)	``			-
Negative and Trace	82 (100)	45 (100)	37 (100)	
Urobilinogen (n=86)		/	/	0.515
Negative and Trace	55 (67.07)	30 (66.67)	25 (67.57)	
0.1	23 (28.05)	13 (28.89)	10 (27.03)	
0.2	1(1.22)	$\begin{array}{c} 0 \\ 2 & (4 & 4 & 4) \end{array}$	1 (2.7)	
1 2	2 (2.44)	2 (4.44)	0 1 (2 7)	
2	1 (1.22)	0	1 (2.7)	
				0.040
Leukocytes (n=82)	70 (06 24)	12 (02 22)	27(100)	0.248
Negative and Trace	79 (96.34)	42 (93.33)	37 (100)	
1	3 (3.66)	3 (6.67)	0	
Microscopic				
•				0.005
RBC (n=86)	15 (50 22)	22 (44.0)	22(6210)	0.227
0 to 5 6 to 20	45 (52.33)	22(44.9)	23 (62.16)	
6 to 20 > 20	23 (26.74) 18 (20.93)	14 (28.57) 13 (26.53)	9 (24.32) 5 (13.51)	
~ 20	10 (20.75)	15 (20.55)	5 (15.51)	

WBC (n=86)				0.509
0 to 5	52 (60.47)	27 (55.1)	25 (67.57)	
6 to 20	24 (27.91)	15 (30.61)	9 (24.32)	
> 20	10 (11.63)	7 (14.29)	3 (8.11)	
Epithelial Cells (n=86)	- ()		- /- //	0.488
None	5 (5.81)	3 (6.12)	2 (5.41)	
Few/rare	30 (34.88)	18 (36.73)	12 (32.43)	
Occasional/Moderate	44 (51.16)	26 (53.06)	18 (48.65)	
Many	7 (8.14)	2 (4.08)	5 (13.51)	
Mucus Threads (n=86)				0.150
None	4 (4.65)	1 (2.04)	3 (8.11)	
Few/rare	44 (51.16)	25 (51.02)	19 (51.35)	
Occasional/Moderate	29 (33.72)	20 (40.82)	9 (24.32)	
Many	9 (10.47)	3 (6.12)	6 (16.22)	
Paotoria $(n-96)$				0.038
Bacteria (n=86) None	1 (1 16)	0	1 (2 7)	0.030
	1(1.16)		1(2.7)	
Few/rare	51 (59.3)	24 (48.98)	27 (72.97)	
Occasional/Moderate	27 (31.4)	19 (38.78)	8 (21.62)	
Many	7 (8.14)	6 (12.24)	1 (2.7)	
Yeast Cells (n=86)				0.622
None	80 (93.02)	47 (95.92)	33 (89.19)	
Few/rare	2 (2.44)	1 (2.04)	1 (2.7)	
Occasional/Moderate	1 (1.16)	0	1 (2.7)	
Many	3 (3.49)	1 (2.04)	2 (5.41)	
Crystals				
Amorphous urates				0.001
(n=84)	9 (10.71)	4 (8.51)	5 (13.51)	0.001
None	30 (35.71)	9 (19.15)	21 (56.76)	
Few/rare	34 (40.48)	26 (55.32)	8 (21.62)	
Occasional/Moderate	11 (13.1)	8 (17.02)	3 (8.11)	
Many	11 (13.1)	0 (17.02)	5 (0.11)	

Amorphous				0.682
phosphate (n=86)	79 (91.86)	45 (91.84)	34 (91.89)	
None	2 (2.33)	1 (2.04)	1 (2.7)	
Few/rare	3 (3.49)	1 (2.04)	2 (5.41)	
Occasional/Moderate	2 (2.33)	2 (4.08)	0	
Many	``'	~ /		
Casts (n=86)				
Coarse granular	9 (10.47)	7 (14.29)	2 (5.41)	0.289
	9 (10.47) 5 (5.81)	7 (14.29) 1 (2.04)	2 (5.41) 4 (10.81)	0.289 0.160
Coarse granular				0.160
Coarse granular Fine granular	5 (5.81)	1 (2.04)	4 (10.81)	

AKI, acute kidney injury; IQR, interquartile range; RBC, red blood cells; WBC, whiteblood cells

Table 3. Frequency of Renal Function According to Staging of AKI Based on 399

400 KDIGO 2012 (n=81)

	Frequency (%)		
AKI stage 1	40 (49.38)		
AKI Stage 2	12 (14.81)		
AKI Stage 3	29 (35.8)		

AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes 401


	Total (n=195)	With AKI (n=81, 42%)	Without AKI (n=114, 58%)	p-value
	Freque	ncy (%); Media		-
Mortality				<0.001
Expired	55 (28.21)	41 (50.62)	14 (12.28)	
Discharged	140 (71.79)	40 (49.38)	100 (87.72)	
Length of Hospital Stay	21 (12 to 27)	20 (8 to 26)	21 (15 to 28)	0.053
Morbidity				
Nasal cannula	74 (47.95)	31 (38.27)	43 (37.72)	1.000
Facemask	28 (14.36)	15 (18.52)	13 (11.4)	0.214
High flow nasal cannula	10 (5.13)	5 (6.17)	5 (4.39)	0.744
Mechanical ventilation	37 (18.97)	26 (32.1)	11 (9.65)	<0.001
Renal replacement therapy				<0.001
Yes	27 (13.85)	25 (30.86)	2 (1.75)	
No	168 (86.15)	56 (69.14)	112 (98.25)	

Table 4. Assessment of Outcome of Patients With AKI vs. Those Without 403

	404	AKI, acute	kidney	injury;	IQR,	interquartile range
--	-----	------------	--------	---------	------	---------------------

	AKI Stage 1	AKI Stage 2	AKI Stage 3		
	(n=40)	(n=12)	(n=29)		
	Frequency (%); Median (IQR)				
Mortality					
Expired	15 (37.5)	5 (41.67)	21 (72.41)		
Discharged	25 (62.5)	7 (58.33)	8 (27.59)		
Length of Hospital Stay	21 (8 to 26)	24 (14 to 30)	10 (4 to 25)		
Renal replacement therapy					
Yes	5 (12.5)	2 (16.67)	18 (62.07)		
No	35 (87.5)	10 (83.33)	11 (37.93)		

Table 5. Assessment of Outcomes in Patients Based on AKI Stage



Figure